Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Non-Current Debt (2016 - 2017)

Lineage Cell Therapeutics' Non-Current Debt history spans 3 years, with the latest figure at $18000.0 for Q4 2017.

  • For Q4 2017, Non-Current Debt fell 85.0% year-over-year to $18000.0; the TTM value through Dec 2017 reached $18000.0, down 85.0%, while the annual FY2017 figure was $18000.0, 85.0% down from the prior year.
  • Non-Current Debt reached $18000.0 in Q4 2017 per LCTX's latest filing, down from $44000.0 in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $268000.0 in Q3 2015 to a low of $18000.0 in Q4 2017.
  • Average Non-Current Debt over 3 years is $142600.0, with a median of $146500.0 recorded in 2016.
  • Peak YoY movement for Non-Current Debt: crashed 35.45% in 2016, then tumbled 85.0% in 2017.
  • A 3-year view of Non-Current Debt shows it stood at $220000.0 in 2015, then tumbled by 45.45% to $120000.0 in 2016, then crashed by 85.0% to $18000.0 in 2017.
  • Per Business Quant, the three most recent readings for LCTX's Non-Current Debt are $18000.0 (Q4 2017), $44000.0 (Q3 2017), and $95000.0 (Q2 2017).